Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function.
Ravindran
Lakshmi N
LN
Eisfeld
Beata S
BS
Kennedy
Sidney H
SH
D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D003865:Major Depressive Disorder / Q000188:drug therapy*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D000068736:Duloxetine Hydrochloride; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008803:Mianserin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000078785:Mirtazapine; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D020018:Sexual Dysfunctions, Psychological / Q000139:chemically induced* / Q000188:drug therapy; D013876:Thiophenes / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
D018759:Adrenergic Uptake Inhibitors; D000068736:Duloxetine Hydrochloride; D006634:Histamine H1 Antagonists; D008803:Mianserin; D000078785:Mirtazapine; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes